National Institutes of Health (NIH) Awards Intrinsic LifeSciences $4.45 Million SBIR Phase II-B Funding For A Diagnostic Test For The Differential Diagnosis Of Anemias With The Iron Regulatory Hormone, Hepcidin
7/29/2014 10:05:17 AM
LA JOLLA, Calif.--(BUSINESS WIRE)--Intrinsic LifeSciences™ (ILS) is a privately held diagnostics company focused on developing novel hepcidin diagnostic tests, iron biomarker panels, and algorithms for genetic and acquired iron and inflammatory diseases. Today, ILS announced it has been awarded a $4.45 million grant from the National Institutes of Health for its Phase II-B Small Business Innovation Research project entitled, “Serum Hepcidin Immunoassay: Laboratory to Marketplace.” With the pre-commercialization funding, ILS will establish cGMP/ISO compliant manufacturing of the Intrinsic Hepcidin Index™ in vitro diagnostic, and perform a prospective clinical study at Boston Children’s Hospital under the direction of Mark D. Fleming, M.D., D. Phil. (Pathologist-in-Chief). The study aims to clinically validate the Hepcidin Index test for the differential diagnosis of a recently discovered genetic iron disorder, Iron Refractory Iron Deficiency Anemia (IRIDA), from other acquired forms of microcytic anemia.
Help employers find you! Check out all the jobs and post your resume.
comments powered by